Compass Therapeutics Inc. (CMPX) Stock Forecast & Price Target
Compass Therapeutics Inc. · NASDAQ
$2.09+0.02 (+0.97%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Compass Therapeutics Inc, 8 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $7.00 to $30.00 (about 4.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $15.50 sits 642% above the current $2.09. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.11 next quarter toward $-0.46 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Moderate Buy
Strong Buy00%
Buy8100%
Hold00%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Compass Therapeutics Inc.
As of Jul, 8 of 8 firms rate CMPX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CMPX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.12 – $-0.08 · 12 analysts · +32% YoY
Next period, 12 analysts expect Compass Therapeutics Inc. to earn $-0.11 a share (range $-0.12 – $-0.08), versus $-0.08 a year earlier. Full-year consensus is $-0.43, growing to $-0.46 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 12 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $-2.1M, rising to $25.3M next year.
Top analysts covering Compass Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CMPX.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$12.00+474.2% to target
Overall win rate
55%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #167
Buy
$11.00+426.3% to target
Overall win rate
50%
+ Follow
#3
Li Watsek
Cantor Fitzgerald · Rank #218
Buy
No targeton CMPX
Overall win rate
38%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$24.00+1048.3% to target
Overall win rate
32%
+ Follow
#5
Reni J. Benjamin
JMP Securities · Rank #290
Buy
$10.00+378.5% to target
Overall win rate
33%
+ Follow
CMPX stock forecast FAQ
What is CMPX's average 12-month price target?+
The 5 analysts with a live target average $15.50 for Compass Therapeutics Inc. over the next 12 months, ranging from a $30.00 high to a $7.00 low.
Is CMPX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 8 analyst ratings, 8 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CMPX?+
The Street-high target is $30.00 (D. Boral Capital), and the Street-low is $7.00 (Canaccord Genuity). The average of all 5 active targets is $15.50.
How many Wall Street analysts cover CMPX?+
8 analysts have an active rating on Compass Therapeutics Inc., and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering CMPX?+
Among analysts who currently cover CMPX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $12.00 target.
What is Compass Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.12 – $-0.08) across 12 analysts. Full-year EPS is projected at $-0.43, rising to $-0.46 the following year.
How much revenue is Compass Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $-2.1M, growing to $25.3M next year.
Have analysts been upgrading or downgrading CMPX lately?+
As of Jul, 8 of 8 firms rate CMPX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CMPX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
